Across TCGA pan-cancer cohorts, TFEC mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated TFEC data layer compared with 21 for mass-spec protein and 4 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TFEC mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TFEC expression acts as an unfavorable survival marker.
LUAD are the cancer types where TFEC mass-spec protein most reproducibly stratifies survival.